TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22700038

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-MDMA (125 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pretreatment-placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pretreatment-MDMA
Number of subjects: 16
Study: 22700780

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Combination of auscultation and LUS
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Follow-up measurements
Number of subjects: 362
Study: 22700836

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A)
Number of subjects: 404
Study: 22700841

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) diagnosis through pre-operative polysomnography
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pre-operative polysomnography
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Age- and sex-adjusted multivariate regression analysis
Number of subjects: 82
Study: 22701330

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 15000
Study: 22701542

Group type: EXPERIMENTAL
Intervention: Daily supervised exercise for two weeks
Number of subjects: 60
Study: 22701615

Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg, 200 mg, or 300 mg daily) combined with cetuximab and irinotecan
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vandetanib with cetuximab and irinotecan
Number of subjects: 27
Study: 22704876

Group type: EXPERIMENTAL
Intervention: OPG levels ≥ 75th percentile
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: OPG levels in the highest quartile
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: OPG1 as a continuous variable
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: OPG serum levels collected 24h after infarction
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: High OPG levels
Number of subjects: 221
Study: 22705432

Group type: EXPERIMENTAL
Intervention: Anaemia prevalence assessment
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Iron deficiency assessment using Green and King's index
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Electrophoresis on a subsample
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Stunting and wasting assessment
Number of subjects: 1269
Study: 22706476

Group type: EXPERIMENTAL
Intervention: Post-occlusive reactive hyperemia induced through vascular occlusion (using limb tourniquet or clamping the pedicle of a skin flap).
Number of subjects: 12
Study: 22707516

Group type: EXPERIMENTAL
Intervention: Bevacizumab, 5 mg/kg or 10 mg/kg every 2 weeks
Number of subjects: 43
Study: 22708895

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide loading dose of 200 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide loading dose of 300 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide loading dose of 400 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 100
Study: 22709460

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 8062

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 8062

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 8062

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 8062

Group type: EXPERIMENTAL
Intervention: Neuraxial anaesthesia
Number of subjects: 8062

Group type: EXPERIMENTAL
Intervention: Combination anaesthesia (general + peripheral nerve block or neuraxial + peripheral nerve block)
Number of subjects: 8062
Study: 22709477

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 3 weeks in-hospital and continued at home for 12 weeks
Number of subjects: 21
Study: 22709833

Group type: EXPERIMENTAL
Intervention: Fenofibrate (± statin) for up to 5 years
Number of subjects: 11388
Study: 22710249

Group type: EXPERIMENTAL
Intervention: Waveguide-based optical biosensor for the detection of TB-specific biomarkers (LAM, ESAT6, Ag85)
Number of subjects: 0
Study: 22713099

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 30μg-drospirenone 3mg plus metformin 1700 mg daily for 6 months
Number of subjects: 25
Study: 22714121

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 16 weeks
Number of subjects: 0
Study: 22715281

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22716943

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 769
Study: 22717465

Group type: EXPERIMENTAL
Intervention: Supervised, moderately intense aerobic and resistance exercise program for 10 weeks
Number of subjects: 17
Study: 22717743

Group type: EXPERIMENTAL
Intervention: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec) administered at 3 × 10(11) gc kg(-1) for cohorts 1 (n=2) and 2 (n=4) and 1 × 10(12) gc kg(-1) for cohort 3 (n=8). Immunosuppressants were also given to cohorts 2 and 3 for 12 weeks.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec)
Number of subjects: 14
Study: 22719020

Group type: EXPERIMENTAL
Intervention: STAT3 decoy oligonucleotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic STAT3 decoy
Number of subjects: 0
Study: 22719806

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 45

Group type: COMPARATOR
Intervention: African Americans (AAs)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Adjustment for 25(OH)D
Number of subjects: 45
Study: 22719881

Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 35
Study: 22719933

Group type: EXPERIMENTAL
Intervention: qLAMP (quantitative Loop-mediated isothermal Amplification)
Number of subjects: 2986

Group type: COMPARATOR
Intervention: Standard bacterial cultures
Number of subjects: 2986
Study: 22719975

Group type: EXPERIMENTAL
Intervention: miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combined variables (sepsis stage, SOFA scores, APACHE II scores, miR-15a, miR-16, miR-193b*, and miR-483-5p)
Number of subjects: 214

Group type: COMPARATOR
Intervention: APACHE II scores
Number of subjects: 214

Group type: COMPARATOR
Intervention: SOFA scores
Number of subjects: 214

Group type: COMPARATOR
Intervention: Procalcitonin levels
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: miR-193b*
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combined variables
Number of subjects: 214
Study: 22721660

Group type: EXPERIMENTAL
Intervention: Coronary reactivity testing (CRT)
Number of subjects: 293
Study: 22721944

Group type: EXPERIMENTAL
Intervention: Walking distance (six-minute walking distance)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fat-free mass index (FFMI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PaCO2 levels
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Post-ischemic reactive hyperemia (RH-PAT) measurement
Number of subjects: 44
Study: 22721971

Group type: EXPERIMENTAL
Intervention: Rapamycin/IL-2 combination therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 9
Study: 22722065

Group type: EXPERIMENTAL
Intervention: Nonbothersome tinnitus group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal healthy nontinnitus control group
Number of subjects: 18
Study: 22722717

Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB) in transarterial chemoembolization (TACE), 100-300 μm beads loaded with ≤100 mg doxorubicin, up to four sessions within 6 months.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB) in transarterial chemoembolization (TACE)
Number of subjects: 13
Study: 22722755

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunospot assay
Number of subjects: 25

Group type: COMPARATOR
Intervention: Skin testing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunospot assay (within 2 years of drug reaction)
Number of subjects: 25
Study: 22722778

Group type: EXPERIMENTAL
Intervention: ACTH gel (80 units subcutaneously twice weekly for 6 months)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ACTH gel
Number of subjects: 15
Study: 22723305

Group type: EXPERIMENTAL
Intervention: Vascular profiling using coronary angiography and intravascular ultrasound; assessed at baseline and 6 to 10 months later.
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Baseline large plaque burden and low endothelial shear stress as predictors.
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Combination of independent baseline predictors.
Number of subjects: 506
Study: 22723326

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapies (AET; leuprolide, tamoxifen, aromatase inhibitors)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metabolic activity in the insula and hypothalamus measured by rCMRglu
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Response to AET
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype
Number of subjects: 18
Study: 22723441

Group type: EXPERIMENTAL
Intervention: Insulin activation of fatty acid uptake
Number of subjects: 15

Group type: COMPARATOR
Intervention: Suppression of adipose fatty acid release
Number of subjects: 15
Study: 22723456

Group type: EXPERIMENTAL
Intervention: eGFR in patients with WMH Grade 0 to 1 (none to mild)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: eGFR in patients with WMH Grade 2 (moderate)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: eGFR in patients with WMH Grade 3 (severe)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Association of WMH with age
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Association of WMH with hypertension
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Association of WMH with cardiovascular disease
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Association of WMH with overweight (BMI >25 kg/m(2))
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Association of WMH with current smoking
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Association of WMH with eGFR
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of WMH severity
Number of subjects: 2009
Study: 22723579

Group type: EXPERIMENTAL
Intervention: AHSCT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AHSCT in non-DKA patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AHSCT in DKA patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AHSCT in non-DKA group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AHSCT in DKA group
Number of subjects: 28
Study: 22723585

Group type: EXPERIMENTAL
Intervention: Fructose (isocaloric exchange for carbohydrate)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control (carbohydrate)
Number of subjects: 209
Study: 22726923

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 0
Study: 22727048

Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy with insulin detemir / insulin aspart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human NPH insulin / human regular insulin
Number of subjects: 0
Study: 22727547

Group type: EXPERIMENTAL
Intervention: Dietary energy density of solid food
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Energy intake (kcal/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Systemic inflammation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Energy intake after adjustment for survival and inflammatory status
Number of subjects: 107

Group type: COMPARATOR
Intervention: Total diet energy density
Number of subjects: 107
Study: 22729476

Group type: EXPERIMENTAL
Intervention: Study Coordinator Role
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Study-wide leadership activities
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Functional consistency across sites
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Participant retention and data completion rates
Number of subjects: 28
Study: 22730421

Group type: EXPERIMENTAL
Intervention: Repaired tetralogy of Fallot (TOF)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 483
Study: 22730482

Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (hsCRP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Soluble tumour necrosis factor receptor (sTNFR-1)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 326
Study: 22731653

Group type: EXPERIMENTAL
Intervention: Eszopiclone 1 mg (elderly)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg (elderly)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg (nonelderly)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg (nonelderly)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Eszopiclone (1 mg or 2 mg for elderly; 2 mg or 3 mg for nonelderly)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 325
Study: 22732334

Group type: EXPERIMENTAL
Intervention: HX575 (biosimilar epoetin-α) administered intravenously aiming for hemoglobin (Hb) target of 10 - 12 g/dl
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: HX575 (biosimilar epoetin-α)
Number of subjects: 1500
Study: 22732895

Group type: EXPERIMENTAL
Intervention: Serum miRNAs (specifically the miR-200b/429 cluster)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum miRNAs (miR-200b/429 cluster)
Number of subjects: 0
Study: 22733017

Group type: EXPERIMENTAL
Intervention: Anti-plasma cell therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 76
Study: 22733020

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Metastatic bone surveys
Number of subjects: 303
Study: 22733373

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg IV 30 min before chemotherapy
Number of subjects: 34
Study: 22733887

Group type: EXPERIMENTAL
Intervention: Hydrogen-1 MR spectroscopy (1H-MRS)
Number of subjects: 52
Study: 22733916

Group type: COMPARATOR
Intervention: Without feedback
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: With feedback
Number of subjects: 100
Study: 22734012

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus cisplatin 60 mg/m² (day 1), followed by oral capecitabine 1875 mg/m² divided into two doses (days 1-14) every 3 weeks; three cycles preoperatively and three cycles postoperatively
Number of subjects: 51
Study: 22734071

Group type: EXPERIMENTAL
Intervention: R-CHOP plus bevacizumab
Number of subjects: 64
Study: 22734119

Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture treatment
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 270
Study: 22734817

Group type: EXPERIMENTAL
Intervention: Anemia (defined as Hb <11.0 g/dl in children <5 years or <11.5 g/dl in children 5-12 years)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Routine iron supplementation
Number of subjects: 299
Study: 22735035

Group type: EXPERIMENTAL
Intervention: Exenatide administration for an average of 84 ± 5 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exenatide administration
Number of subjects: 18
Study: 22735195

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study: 22735430

Group type: EXPERIMENTAL
Intervention: No radiotherapy (47 patients who achieved complete response after 2 cycles)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 25.5 Gy-involved-field radiotherapy (41 patients with less than complete response)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall cohort (both groups combined)
Number of subjects: 88
Study: 22735793

Group type: EXPERIMENTAL
Intervention: Ambulatory systolic blood pressure (24-h, daytime, night-time)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Central systolic blood pressure
Number of subjects: 460
Study: 22736422

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Crossover from medical management to ESS
Number of subjects: 98

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 98
Study: 22736604

Group type: EXPERIMENTAL
Intervention: Novel cancer cell vaccine for prostate cancer
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intravenous aciclovir and dexamethasone
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Postmortem examination
Number of subjects: 1
Study: 22736616

Group type: EXPERIMENTAL
Intervention: Conjunctival swabbing for bacterial pathogens
Number of subjects: 148
Study: 22738806

Group type: EXPERIMENTAL
Intervention: Pregnancy registry system
Number of subjects: 72848
Study: 22739225

Group type: EXPERIMENTAL
Intervention: Participant preference study using the modified San Francisco Stop Smoking Internet site
Number of subjects: 7763

Group type: COMPARATOR
Intervention: Previous randomized controlled trials (RCTs)
Number of subjects: 7763
Study: 22739576

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 263
Study: 22740718

Group type: EXPERIMENTAL
Intervention: Maraviroc added to existing ART for 24 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (existing ART without maraviroc)
Number of subjects: 34
Study: 22742414

Group type: EXPERIMENTAL
Intervention: Self-reported triggers (mean of 12 triggers)
Number of subjects: 296
Study: 22742719

Group type: EXPERIMENTAL
Intervention: Low 10-year (<10%)/low lifetime (<39%) predicted risk group
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Low 10-year (<10%)/high lifetime (≥39%) predicted risk group
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: High 10-year (≥10%) predicted risk or diagnosed diabetes group
Number of subjects: 2070
Study: 22742742

Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU i.v. with additional titration steps of 600 IU and/or continuous infusion if necessary
Number of subjects: 109
Study: 22742881

Group type: EXPERIMENTAL
Intervention: IV busulfan (0.8-1.2 mg/kg) administered four times daily for 4 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Oral busulfan (1.45-1.55 mg/kg) administered four times daily for 4 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: IV busulfan
Number of subjects: 63
Study: 22742890

Group type: EXPERIMENTAL
Intervention: Pentoxifylline, tocopherol, and clodronate (PENTOCLO)
Number of subjects: 0
Study: 22743310

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid ALA (highest quartile)
Number of subjects: 2957

Group type: EXPERIMENTAL
Intervention: Dietary ALA (highest quartile)
Number of subjects: 2957
Study: 22743380

Group type: EXPERIMENTAL
Intervention: PAMI with coronary injury (6 patients, 11.76%)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PAMI without coronary injury (10 patients, 19.6%)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Risk factors for PAMIWCI
Number of subjects: 51

Group type: COMPARATOR
Intervention: No relationship found
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: PAMI incidence
Number of subjects: 51
Study: 22744013

Group type: EXPERIMENTAL
Intervention: Higher cumulative risk
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Higher levels of promotive factors
Number of subjects: 726
Study: 22744195

Group type: EXPERIMENTAL
Intervention: PEG-3350 mixed with 1.9 L of Gatorade
Number of subjects: 46
Study: 22745608

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 2236

Group type: COMPARATOR
Intervention: Normal vaginal flora
Number of subjects: 2236
Study: 22747613

Group type: EXPERIMENTAL
Intervention: Valsartan plus hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine plus hydrochlorothiazide
Number of subjects: 0
Study: 22747660

Group type: EXPERIMENTAL
Intervention: docetaxel-based regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sipuleucel-T, cabazitaxel, and abiraterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: various promising candidates/regimens
Number of subjects: 0
Study: 22748805

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) supplementation (3 g/day)
Number of subjects: 30
Study: 22749065

Group type: EXPERIMENTAL
Intervention: Florbetapir PET imaging
Number of subjects: 59
Study: 22750015

Group type: EXPERIMENTAL
Intervention: Oral vitamin D(3) supplementation (0 to 4000 IU/d)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Baseline serum 25 (OH) D
Number of subjects: 318

Group type: COMPARATOR
Intervention: Change in serum 25 (OH) D over 12 weeks
Number of subjects: 318
Study: 22751081

Group type: EXPERIMENTAL
Intervention: Natrelle Style 410 implants
Number of subjects: 941
Study: 22751595

Group type: EXPERIMENTAL
Intervention: IA etanercept injections (12.5 mg, 4 injections every 2 weeks)
Number of subjects: 14
Study: 22751958

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2994
Study: 22752026

Group type: EXPERIMENTAL
Intervention: Insulin-mediated myocardial glucose disposal assessed with 2-deoxy-2-[(18)F]fluoroglucose PET.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Number of subjects: 24
Study: 22752222

Group type: EXPERIMENTAL
Intervention: Horizontal-hinge group
Number of subjects: 657

Group type: COMPARATOR
Intervention: Vertical-hinge group
Number of subjects: 657
Study: 22752464

Group type: EXPERIMENTAL
Intervention: Contrast echocardiography
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 110